Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Dementia Alzheimer's Disease

Cannabidiol shows promise for treating Alzheimer’s in mice by targeting brain hyperactivity

by Eric W. Dolan
May 26, 2025
in Alzheimer's Disease, Cannabis
[Adobe Stock]

[Adobe Stock]

Share on TwitterShare on Facebook
Stay on top of the latest psychology findings: Subscribe now!

A new study published in Molecular Psychiatry provides preliminary evidence that cannabidiol, a compound derived from cannabis, may reduce cognitive decline and brain pathology in a mouse model of Alzheimer’s disease. Researchers found that chronic administration of cannabidiol improved memory performance and reduced the accumulation of amyloid-beta plaques—one of the hallmarks of Alzheimer’s. These benefits were linked to cannabidiol’s ability to regulate overactive brain cells in a key region involved in memory.

Cannabidiol, or CBD, is one of the main components of cannabis. Unlike tetrahydrocannabinol (THC), it does not produce a high and is generally considered safe. In recent years, researchers have been exploring its potential therapeutic effects on various neurological and psychiatric conditions, including epilepsy, anxiety, and neurodegenerative diseases such as Alzheimer’s. One area of interest is whether CBD can calm excessive brain activity, a problem observed in people and animals with Alzheimer’s disease.

The research team, based in China, conducted a series of experiments to test whether CBD could reduce symptoms of Alzheimer’s in genetically modified mice known as 5×FAD mice. These animals are widely used in research because they develop Alzheimer’s-like symptoms, including memory loss and the buildup of toxic amyloid-beta plaques in the brain. The researchers administered a low daily dose of CBD to these mice for just over a month and then assessed their behavior, brain activity, and the extent of brain pathology.

To evaluate memory function, the mice completed a series of behavioral tests. In a novel object recognition test, CBD-treated mice spent more time exploring new objects, indicating improved recognition memory. In two separate spatial memory tasks—the Morris water maze and the Barnes maze—CBD-treated mice learned the location of a hidden platform more quickly and remembered it better than untreated mice. These improvements in memory occurred without changes in general motor function or anxiety-like behavior, suggesting that CBD had specific effects on cognition.

Beyond behavior, the researchers looked directly at the brains of the mice. They found that CBD treatment led to a reduction in amyloid-beta plaques, particularly in the dentate gyrus, a part of the hippocampus that plays an important role in learning and memory. The reduction was most noticeable in smaller plaques, which are typically newly formed. This suggests that CBD may help slow the formation of new plaques rather than clear out existing ones. Importantly, the extent of plaque reduction in the dentate gyrus was strongly associated with the improvements in memory, highlighting the relevance of this brain region in both pathology and treatment response.

The study also investigated how CBD might achieve these effects at the molecular level. The researchers focused on glycine receptors, which help regulate electrical activity in the brain by dampening excessive neuronal firing. These receptors are particularly abundant in the dentate gyrus. Previous studies have shown that CBD can enhance the activity of glycine receptors by binding to a specific site on the receptor protein.

Using genetic techniques, the researchers disrupted glycine receptor function in some mice to test whether these receptors were necessary for CBD’s effects. In mice where glycine receptors in the dentate gyrus were either knocked down or altered to prevent CBD binding, the beneficial effects of CBD disappeared. These mice showed no improvements in memory and no reduction in amyloid-beta plaques, strongly suggesting that glycine receptors are a key mechanism behind CBD’s therapeutic action.

To explore how this might affect brain function, the researchers used several techniques to measure neuronal activity. In untreated Alzheimer’s model mice, neurons in the dentate gyrus were overly active, firing more rapidly than normal. Chronic CBD treatment reduced this hyperactivity, bringing the cells’ behavior closer to normal levels. This calming effect was not observed in mice with disabled glycine receptors, further reinforcing their central role.

The team also recorded brain activity in living mice by implanting electrodes and using calcium imaging, a technique that tracks real-time cellular activity. They found that after CBD infusion, many neurons in the dentate gyrus showed a marked drop in activity. In contrast, mice with a mutated version of the glycine receptor that could not interact with CBD showed little to no change.

While these findings are promising, there are several limitations to the study. First, the research was conducted in mice, not humans. Although animal models are useful for understanding disease mechanisms and testing treatments, they do not capture all aspects of human Alzheimer’s. Second, the study only used male mice, and future research will need to explore whether the same results hold true in females. Third, while the study identified glycine receptors as an important target for CBD, the compound interacts with many other receptors and systems in the brain. More work is needed to understand how these other pathways may contribute to its effects.

Despite these limitations, the findings add to a growing body of evidence suggesting that CBD has potential as a treatment for Alzheimer’s disease. By reducing abnormal brain activity and slowing the formation of harmful plaques, CBD may help preserve memory and cognitive function. The study also highlights the importance of glycine receptors in regulating brain activity and offers a new avenue for therapeutic intervention.

The study, “Cannabidiol ameliorates cognitive decline in 5×FAD mouse model of Alzheimer’s disease through potentiating the function of extrasynaptic glycine receptors,” was authored by Jin Jin, Chonglei Fu, Jing Xia, Heyi Luo, Xianglian Wang, Si Chen, Huanhuan Mao, Kai Yuan, Lin Lu, Wei Xiong, and Guichang Zou.

TweetSendScanShareSendPin1ShareShareShareShareShare

RELATED

A surprising body part might provide key insights into schizophrenia risk
Alzheimer's Disease

New research identifies four distinct health pathways linked to Alzheimer’s disease

July 11, 2025

Researchers identified four common disease pathways—centered on mental health, brain disorders, cognitive decline, and vascular issues—that often precede Alzheimer’s, showing that the sequence of conditions may better predict risk than individual diagnoses alone.

Read moreDetails
New study finds online self-reports may not accurately reflect clinical autism diagnoses
Alzheimer's Disease

Small folds in the brain may hold key insights into Alzheimer’s and aging-related cognitive decline

July 2, 2025

Smaller, shallow brain folds in the posteromedial cortex show greater thinning with age and Alzheimer’s disease, and their structure is closely linked to memory and executive function, suggesting they may be key markers of cognitive decline.

Read moreDetails
Taking medicinal cannabis oil for insomnia does not impair cognition on the following day
Cannabis

Cannabis oil might help with drug-resistant epilepsy, study suggests

July 2, 2025

Nineteen patients with drug-resistant epilepsy experienced seizure freedom after cannabis oil treatment, with a median seizure-free duration of 245 days. Five remained seizure-free for over a year, and most reported improved quality of life and reduced seizure frequency.

Read moreDetails
Cannabis intoxication alters metabolism, but frequent users show fewer effects
Cannabis

Regular cannabis use linked to changes in brain activity regulating movement

June 20, 2025

Researchers have discovered that frequent cannabis users show reduced spontaneous brain activity in the motor cortex, and this neural suppression is tied to cannabis use severity and response speed, even though overall task performance remained comparable to non-users.

Read moreDetails
Poor sleep may shrink brain regions vulnerable to Alzheimer’s disease, study suggests
Alzheimer's Disease

Poor sleep may shrink brain regions vulnerable to Alzheimer’s disease, study suggests

June 14, 2025

Spending less time in slow wave and REM sleep may accelerate brain atrophy in regions affected early in Alzheimer’s disease, according to new research. The findings support sleep quality as a potential factor in preserving brain health.

Read moreDetails
Neuroscience discoveries: 5 new studies offer unexpected insights into the brain
Alzheimer's Disease

Common sleep aid blocks brain inflammation and tau buildup in Alzheimer’s model

June 13, 2025

Scientists have found that lemborexant not only increased restorative sleep in male mice but also reduced levels of toxic tau and brain inflammation. The findings suggest that targeting the brain’s orexin system may help slow Alzheimer’s progression.

Read moreDetails
Older adults adhering to Mediterranean diet have 11% lower odds of developing dementia, study finds
Alzheimer's Disease

Mediterranean diet appears to weaken the depression–Alzheimer’s connection

June 7, 2025

A new study suggests that the Mediterranean diet may reduce the biological impact of depression on the brain. In older men, depressive symptoms were linked to higher Alzheimer’s biomarkers—except in those with strong adherence to a Mediterranean-style diet.

Read moreDetails
Cannabis and appetite: Scientists uncover the brain mechanism behind the munchies
Cannabis

The ‘entourage effect’ — what we don’t know about how cannabis works

June 2, 2025

Cannabis products promise custom experiences based on compound profiles, but the science behind these claims remains limited. While ideas like the “entourage effect” are popular, research on how cannabis compounds interact in humans is still in its early stages.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Neuroscientists shed new light on how heroin disrupts prefrontal brain function

New research identifies four distinct health pathways linked to Alzheimer’s disease

A surprising body part might provide key insights into schizophrenia risk

Religious belief linked to lower anxiety and better sleep in Israeli Druze study

A common vegetable may counteract brain changes linked to obesity

Massive psychology study reveals disturbing truths about Machiavellian leaders

Dementia: Your lifetime risk may be far greater than previously thought

Psychopathic tendencies may be associated with specific hormonal patterns

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy